$3.88 EPS Expected for Affiliated Managers Group, Inc. (AMG); Progenics Pharmaceuticals (PGNX) SI Increased By 6.99%

April 25, 2018 - By Marie Mckinney

Progenics Pharmaceuticals Inc (NASDAQ:PGNX) had an increase of 6.99% in short interest. PGNX’s SI was 9.21M shares in April as released by FINRA. Its up 6.99% from 8.61M shares previously. With 1.74M avg volume, 5 days are for Progenics Pharmaceuticals Inc (NASDAQ:PGNX)’s short sellers to cover PGNX’s short positions. The SI to Progenics Pharmaceuticals Inc’s float is 13.15%. The stock increased 0.86% or $0.06 during the last trading session, reaching $7.03. About 149,214 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has declined 32.66% since April 25, 2017 and is downtrending. It has underperformed by 44.21% the S&P500.

Analysts expect Affiliated Managers Group, Inc. (NYSE:AMG) to report $3.88 EPS on May, 7.They anticipate $0.67 EPS change or 20.87% from last quarter’s $3.21 EPS. AMG’s profit would be $211.45M giving it 10.90 P/E if the $3.88 EPS is correct. After having $4.68 EPS previously, Affiliated Managers Group, Inc.’s analysts see -17.09% EPS growth. The stock increased 0.14% or $0.24 during the last trading session, reaching $169.2. About 167,504 shares traded. Affiliated Managers Group, Inc. (NYSE:AMG) has risen 16.50% since April 25, 2017 and is uptrending. It has outperformed by 4.95% the S&P500.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 9 report. The rating was maintained by Jefferies with “Buy” on Thursday, June 8. The rating was maintained by Brean Capital on Thursday, August 6 with “Buy”. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Friday, August 7 by Zacks. Needham maintained it with “Buy” rating and $11 target in Friday, August 7 report. The stock has “Strong Buy” rating by Needham on Monday, February 6. On Tuesday, September 26 the stock rating was maintained by Jefferies with “Buy”. On Friday, October 23 the stock rating was upgraded by Jefferies to “Buy”. On Thursday, October 27 the stock rating was initiated by Aegis Capital with “Buy”. The firm has “Buy” rating given on Tuesday, June 20 by Needham.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $510.81 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Investors sentiment increased to 1.22 in 2017 Q4. Its up 0.11, from 1.11 in 2017Q3. It increased, as 11 investors sold Progenics Pharmaceuticals, Inc. shares while 40 reduced holdings. 22 funds opened positions while 40 raised stakes. 56.89 million shares or 3.42% less from 58.90 million shares in 2017Q3 were reported. The New York-based Amalgamated Savings Bank has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Ameriprise Financial reported 360,809 shares. Parametric Associate Limited Liability Company accumulated 0% or 194,031 shares. Reilly Fincl Advsrs Ltd Limited Liability Company holds 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) or 1,300 shares. Cwm Ltd owns 33 shares for 0% of their portfolio. Fifth Third Bankshares reported 5,000 shares. Stevens Capital Mngmt L P invested in 0% or 14,271 shares. The California-based Lpl Financial Ltd Limited Liability Company has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Blair William & Il accumulated 26,500 shares. Swiss Bancorporation invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). 189,618 were accumulated by Invesco. Assetmark has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Bank & Trust Of New York Mellon reported 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Price T Rowe Associate Md invested in 111,340 shares. Fuller & Thaler Asset Management owns 337,800 shares for 0.02% of their portfolio.

Affiliated Managers Group, Inc., through its affiliates, operates as an asset management firm providing investment management services to mutual funds, institutional clients, and high net worth individuals in the United States. The company has market cap of $9.22 billion. It provides advisory or subadvisory services to mutual funds. It has a 14.06 P/E ratio. These funds are distributed to retail and institutional clients directly and through intermediaries, including independent investment advisors, retirement plan sponsors, broker-dealers, major fund marketplaces, and bank trust departments.

Among 10 analysts covering Affiliated Managers Group (NYSE:AMG), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Affiliated Managers Group had 54 analyst reports since August 9, 2015 according to SRatingsIntel. The stock of Affiliated Managers Group, Inc. (NYSE:AMG) earned “Buy” rating by Deutsche Bank on Monday, July 18. The rating was downgraded by Citigroup to “Neutral” on Tuesday, December 15. The rating was maintained by Deutsche Bank on Friday, September 18 with “Buy”. The rating was maintained by Standpoint Research on Sunday, August 9 with “Hold”. The firm has “Buy” rating by Deutsche Bank given on Friday, August 5. The firm has “Neutral” rating given on Wednesday, January 3 by Credit Suisse. Goldman Sachs maintained the shares of AMG in report on Monday, March 21 with “Buy” rating. The stock of Affiliated Managers Group, Inc. (NYSE:AMG) earned “Buy” rating by Deutsche Bank on Wednesday, October 5. Wood maintained it with “Outperform” rating and $196 target in Tuesday, August 2 report. Citigroup maintained the shares of AMG in report on Thursday, April 14 with “Neutral” rating.

By1 Marie Mckinney